Relmada Therapeutics, Inc. (RLMD)
7.48
+0.48
(+6.86%)
USD |
NASDAQ |
Apr 17, 16:00
7.77
+0.29
(+3.88%)
After-Hours: 06:57
Relmada Therapeutics SG&A Expense (Quarterly) : 12.26M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 48.23M |
| Theravance Biopharma, Inc. | 20.96M |
| Avalo Therapeutics, Inc. | 6.534M |
| AN2 Therapeutics, Inc. | 2.437M |
| ACADIA Pharmaceuticals, Inc. | 155.62M |